fda semaglutide warning september 2025 Medscape | The has approved once-daily oral 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. ⁠ Beyond the Headlines: FDA Warning

Sodhi said that although the conditions are rare, the medications widespread popularity means that if 1 million people are prescribed those drugs, tens or even hundreds of thousands of people could experience them

Long-term studies are needed to fully understand the sustained impact on weight and potential long-term risks

First, it directly addresses the root cause of mast cell hyper-reactivity: intracellular oxidative stress

Understanding this connection helps patients and providers make informed decisions about treatment and hair health management

GLP-1 medications slow gastric emptying and alter gut motility, potentially affecting probiotic colonization and efficacy

Hims & Hers did not disclose the terms of either deal.